122 results on '"Ziegler, André"'
Search Results
2. An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions
- Author
-
Chua, Winnie, Cardoso, Victor R., Guasch, Eduard, Sinner, Moritz F., Al-Taie, Christoph, Brady, Paul, Casadei, Barbara, Crijns, Harry J. G. M., Dudink, Elton A. M. P., Hatem, Stéphane N., Kääb, Stefan, Kastner, Peter, Mont, Lluis, Nehaj, Frantisek, Purmah, Yanish, Reyat, Jasmeet S., Schotten, Ulrich, Sommerfeld, Laura C., Zeemering, Stef, Ziegler, André, Gkoutos, Georgios V., Kirchhof, Paulus, and Fabritz, Larissa
- Published
- 2023
- Full Text
- View/download PDF
3. Clinical risk assessment of biotin interference with a high-sensitivity cardiac troponin T assay
- Author
-
Mumma, Bryn, Diercks, Deborah, Twerenbold, Raphael, Valcour, André, Ziegler, André, Schützenmeister, André, Kasapic, Dusanka, and Tran, Nam
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Cardiovascular ,Heart Disease - Coronary Heart Disease ,Heart Disease ,Acute Coronary Syndrome ,Biomarkers ,Biotin ,Cohort Studies ,Diagnostic Tests ,Routine ,False Negative Reactions ,Female ,Humans ,Immunoassay ,Immunologic Tests ,Male ,Middle Aged ,Myocardial Infarction ,Risk Assessment ,Troponin T ,acute myocardial infarction ,biotin ,false negative ,high-sensitivity cardiac troponin T ,immunoassay interference ,risk of misclassification ,Cognitive Sciences ,General Clinical Medicine ,Clinical sciences ,Medical biochemistry and metabolomics - Abstract
Objectives Biotin >20.0 ng/mL (81.8 nmol/L) can reduce Elecsys® Troponin T Gen 5 (TnT Gen 5; Roche Diagnostics) assay recovery, potentially leading to false-negative results in patients with suspected acute myocardial infarction (AMI). We aimed to determine the prevalence of elevated biotin and AMI misclassification risk from biotin interference with the TnT Gen 5 assay. Methods Biotin was measured using an Elecsys assay in two cohorts: (i) 797 0-h and 646 3-h samples from 850 US emergency department patients with suspected acute coronary syndrome (ACS); (ii) 2023 random samples from a US laboratory network, in which biotin distributions were extrapolated for higher values using pharmacokinetic modeling. Biotin >20.0 ng/mL (81.8 nmol/L) prevalence and biotin 99th percentile values were calculated. AMI misclassification risk due to biotin interference with the TnT Gen 5 assay was modeled using different assay cutoffs and test timepoints. Results ACS cohort: 1/797 (0.13%) 0-h and 1/646 (0.15%) 3-h samples had biotin >20.0 ng/mL (81.8 nmol/L); 99th percentile biotin was 2.62 ng/mL (10.7 nmol/L; 0-h) and 2.38 ng/mL (9.74 nmol/L; 3-h). Using conservative assumptions, the likelihood of false-negative AMI prediction due to biotin interference was 0.026% (0-h result; 19 ng/L TnT Gen 5 assay cutoff). US laboratory cohort: 15/2023 (0.74%) samples had biotin >20.0 ng/mL (81.8 nmol/L); 99th percentile biotin was 16.6 ng/mL (68.0 nmol/L). Misclassification risk due to biotin interference (19 ng/L TnT Gen 5 assay cutoff) was 0.025% (0-h), 0.0064% (1-h), 0.00048% (3-h), and
- Published
- 2020
4. Biomarker, Imaging, and Clinical Factors Associated With Overt and Covert Stroke in Patients With Atrial Fibrillation
- Author
-
De Marchis, Gian Marco, Krisai, Philipp, Werlen, Laura, Sinnecker, Tim, Aeschbacher, Stefanie, Dittrich, Tolga D., Polymeris, Alexandros A., Coslovksy, Michael, Blum, Manuel R., Rodondi, Nicolas, Reichlin, Tobias, Moschovitis, Giorgio, Wuerfel, Jens, Lyrer, Philippe A., Fischer, Urs, Conen, David, Kastner, Peter, Ziegler, André, Osswald, Stefan, Kühne, Michael, and Bonati, Leo H.
- Published
- 2023
- Full Text
- View/download PDF
5. Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial
- Author
-
Gkarmiris, Konstantinos I., primary, Lindbäck, Johan, additional, Alexander, John H., additional, Granger, Christopher B., additional, Kastner, Peter, additional, Lopes, Renato D., additional, Ziegler, André, additional, Oldgren, Jonas, additional, Siegbahn, Agneta, additional, Wallentin, Lars, additional, and Hijazi, Ziad, additional
- Published
- 2024
- Full Text
- View/download PDF
6. Automated urinalysis combining physicochemical analysis, on-board centrifugation, and digital imaging in one system: A multicenter performance evaluation of the cobas 6500 urine work area
- Author
-
Cobbaert, Christa M., Arslan, Figen, Caballé Martín, Imma, Serra, Antoni Alsius, Picó-Plana, Ester, Sánchez-Margalet, Víctor, Carmona-Fernández, Antonio, Burden, John, Ziegler, André, and Bechel, Walter
- Published
- 2019
- Full Text
- View/download PDF
7. The Role of Disinfectant Resistance of Salmonella enterica Serotype enteritidis in Recurring Infections in Pennsylvania Egg Quality Assurance Program Monitored Flocks
- Author
-
Davison, Sherrill, Benson, Charles E., Munro, Donald S., Rankin, Shelly C., Ziegler, Andre F., and Eckroade, Robert J.
- Published
- 2003
8. Eustrongylidiasis in Eastern Great Blue Herons (Ardea herodias)
- Author
-
Ziegler, Andre F., Welte, Sallie C., Miller, Erica A., and Nolan, Thomas J.
- Published
- 2000
- Full Text
- View/download PDF
9. Characteristics of H7N2 (Nonpathogenic) Avian Influenza Virus Infections in Commercial Layers, in Pennsylvania, 1997-98
- Author
-
Ziegler, Andre F., Davison, Sherrill, Acland, Helen, and Eckroade, Robert J.
- Published
- 1999
- Full Text
- View/download PDF
10. Comparison of an Antigen-Capture Enzyme Immunoassay with Virus Isolation for Avian Influenza from Field Samples
- Author
-
Davison, Sherrill, Ziegler, Andre F., and Eckroade, Robert J.
- Published
- 1998
- Full Text
- View/download PDF
11. Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation
- Author
-
Benz, Alexander P, primary, Hijazi, Ziad, additional, Lindbäck, Johan, additional, Connolly, Stuart J, additional, Eikelboom, John W, additional, Kastner, Peter, additional, Ziegler, André, additional, Alexander, John H, additional, Granger, Christopher B, additional, Lopes, Renato D, additional, Oldgren, Jonas, additional, Siegbahn, Agneta, additional, and Wallentin, Lars, additional
- Published
- 2023
- Full Text
- View/download PDF
12. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation : the 8th AFNET/EHRA consensus conference
- Author
-
Schnabel, Renate B, Marinelli, Elena Andreassi, Arbelo, Elena, Boriani, Giuseppe, Boveda, Serge, Buckley, Claire M, Camm, A John, Casadei, Barbara, Chua, Winnie, Dagres, Nikolaos, de Melis, Mirko, Desteghe, Lien, Diederichsen, Søren Zöga, Duncker, David, Eckardt, Lars, Eisert, Christoph, Engler, Daniel, Fabritz, Larissa, Freedman, Ben, Gillet, Ludovic, Goette, Andreas, Guasch, Eduard, Svendsen, Jesper Hastrup, Hatem, Stéphane N, Haeusler, Karl Georg, Healey, Jeff S, Heidbuchel, Hein, Hindricks, Gerhard, Hobbs, F D Richard, Hübner, Thomas, Kotecha, Dipak, Krekler, Michael, Leclercq, Christophe, Lewalter, Thorsten, Lin, Honghuang, Linz, Dominik, Lip, Gregory Y H, Løchen, Maja Lisa, Lucassen, Wim, Malaczynska-Rajpold, Katarzyna, Massberg, Steffen, Merino, Jose L, Meyer, Ralf, Mont, Lluıs, Myers, Michael C, Neubeck, Lis, Niiranen, Teemu, Oeff, Michael, Oldgren, Jonas, Potpara, Tatjana S, Psaroudakis, George, Pürerfellner, Helmut, Ravens, Ursula, Rienstra, Michiel, Rivard, Lena, Scherr, Daniel, Schotten, Ulrich, Shah, Dipen, Sinner, Moritz F, Smolnik, Rüdiger, Steinbeck, Gerhard, Steven, Daniel, Svennberg, Emma, Thomas, Dierk, True Hills, Mellanie, van Gelder, Isabelle C, Vardar, Burcu, Palà, Elena, Wakili, Reza, Wegscheider, Karl, Wieloch, Mattias, Willems, Stephan, Witt, Henning, Ziegler, André, Daniel Zink, Matthias, Kirchhof, Paulus, Schnabel, Renate B, Marinelli, Elena Andreassi, Arbelo, Elena, Boriani, Giuseppe, Boveda, Serge, Buckley, Claire M, Camm, A John, Casadei, Barbara, Chua, Winnie, Dagres, Nikolaos, de Melis, Mirko, Desteghe, Lien, Diederichsen, Søren Zöga, Duncker, David, Eckardt, Lars, Eisert, Christoph, Engler, Daniel, Fabritz, Larissa, Freedman, Ben, Gillet, Ludovic, Goette, Andreas, Guasch, Eduard, Svendsen, Jesper Hastrup, Hatem, Stéphane N, Haeusler, Karl Georg, Healey, Jeff S, Heidbuchel, Hein, Hindricks, Gerhard, Hobbs, F D Richard, Hübner, Thomas, Kotecha, Dipak, Krekler, Michael, Leclercq, Christophe, Lewalter, Thorsten, Lin, Honghuang, Linz, Dominik, Lip, Gregory Y H, Løchen, Maja Lisa, Lucassen, Wim, Malaczynska-Rajpold, Katarzyna, Massberg, Steffen, Merino, Jose L, Meyer, Ralf, Mont, Lluıs, Myers, Michael C, Neubeck, Lis, Niiranen, Teemu, Oeff, Michael, Oldgren, Jonas, Potpara, Tatjana S, Psaroudakis, George, Pürerfellner, Helmut, Ravens, Ursula, Rienstra, Michiel, Rivard, Lena, Scherr, Daniel, Schotten, Ulrich, Shah, Dipen, Sinner, Moritz F, Smolnik, Rüdiger, Steinbeck, Gerhard, Steven, Daniel, Svennberg, Emma, Thomas, Dierk, True Hills, Mellanie, van Gelder, Isabelle C, Vardar, Burcu, Palà, Elena, Wakili, Reza, Wegscheider, Karl, Wieloch, Mattias, Willems, Stephan, Witt, Henning, Ziegler, André, Daniel Zink, Matthias, and Kirchhof, Paulus
- Abstract
Despite marked progress in the management of atrial fibrillation (AF), detecting AF remains difficult and AF-related complications cause unacceptable morbidity and mortality even on optimal current therapy. This document summarizes the key outcomes of the 8th AFNET/EHRA Consensus Conference of the Atrial Fibrillation NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eighty-three international experts met in Hamburg for 2 days in October 2021. Results of the interdisciplinary, hybrid discussions in breakout groups and the plenary based on recently published and unpublished observations are summarized in this consensus paper to support improved care for patients with AF by guiding prevention, individualized management, and research strategies. The main outcomes are (i) new evidence supports a simple, scalable, and pragmatic population-based AF screening pathway; (ii) rhythm management is evolving from therapy aimed at improving symptoms to an integrated domain in the prevention of AF-related outcomes, especially in patients with recently diagnosed AF; (iii) improved characterization of atrial cardiomyopathy may help to identify patients in need for therapy; (iv) standardized assessment of cognitive function in patients with AF could lead to improvement in patient outcomes; and (v) artificial intelligence (AI) can support all of the above aims, but requires advanced interdisciplinary knowledge and collaboration as well as a better medico-legal framework. Implementation of new evidence-based approaches to AF screening and rhythm management can improve outcomes in patients with AF. Additional benefits are possible with further efforts to identify and target atrial cardiomyopathy and cognitive impairment, which can be facilitated by AI.
- Published
- 2023
- Full Text
- View/download PDF
13. Bone Morphogenetic Protein 10—A Novel Biomarker to Predict Adverse Outcomes in Patients With Atrial Fibrillation
- Author
-
Hennings, Elisa; https://orcid.org/0000-0003-2616-5535, Blum, Steffen; https://orcid.org/0000-0002-0325-8993, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Knecht, Sven; https://orcid.org/0000-0001-7122-021X, Eken, Ceylan, Lischer, Mirko; https://orcid.org/0000-0001-7088-2801, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Krisai, Philipp; https://orcid.org/0000-0002-4367-2363, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Ammann, Peter, Conte, Giulio; https://orcid.org/0000-0003-2248-3456, De Perna, Maria Luisa; https://orcid.org/0000-0003-1171-7640, Kobza, Richard; https://orcid.org/0000-0003-3988-7262, Blum, Manuel R, Bossard, Matthias; https://orcid.org/0000-0002-8290-661X, Kastner, Peter; https://orcid.org/0000-0001-8744-7152, Ziegler, André; https://orcid.org/0000-0002-9838-8087, Müller, Christian; https://orcid.org/0000-0002-1120-6405, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Pfister, Otmar; https://orcid.org/0000-0002-6155-5494, Zuern, Christine S; https://orcid.org/0000-0001-6625-284X, Conen, David; https://orcid.org/0000-0002-2459-5251, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Hennings, Elisa; https://orcid.org/0000-0003-2616-5535, Blum, Steffen; https://orcid.org/0000-0002-0325-8993, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Knecht, Sven; https://orcid.org/0000-0001-7122-021X, Eken, Ceylan, Lischer, Mirko; https://orcid.org/0000-0001-7088-2801, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Krisai, Philipp; https://orcid.org/0000-0002-4367-2363, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Ammann, Peter, Conte, Giulio; https://orcid.org/0000-0003-2248-3456, De Perna, Maria Luisa; https://orcid.org/0000-0003-1171-7640, Kobza, Richard; https://orcid.org/0000-0003-3988-7262, Blum, Manuel R, Bossard, Matthias; https://orcid.org/0000-0002-8290-661X, Kastner, Peter; https://orcid.org/0000-0001-8744-7152, Ziegler, André; https://orcid.org/0000-0002-9838-8087, Müller, Christian; https://orcid.org/0000-0002-1120-6405, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Pfister, Otmar; https://orcid.org/0000-0002-6155-5494, Zuern, Christine S; https://orcid.org/0000-0001-6625-284X, Conen, David; https://orcid.org/0000-0002-2459-5251, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, and Osswald, Stefan; https://orcid.org/0000-0002-9240-6731
- Abstract
Background Patients with atrial fibrillation (AF) face an increased risk of death and major adverse cardiovascular events (MACE). We aimed to assess the predictive value of the novel atrial‐specific biomarker BMP10 (bone morphogenetic protein 10) for death and MACE in patients with AF in comparison with NT‐proBNP (N‐terminal prohormone of B‐type natriuretic peptide). Methods and Results BMP10 and NT‐proBNP were measured in patients with AF enrolled in Swiss‐AF (Swiss Atrial Fibrillation Study), a prospective multicenter cohort study. A total of 2219 patients were included (median follow‐up 4.3 years [interquartile range 3.9, 5.1], mean age 73±9 years, 73% male). In multivariable Cox proportional hazard models, the adjusted hazard ratio (aHR) associated with 1 ng/mL increase of BMP10 was 1.60 (95% CI, 1.37–1.87) for all‐cause death, and 1.54 (95% CI, 1.35–1.76) for MACE. For all‐cause death, the concordance index was 0.783 (95% CI, 0.763–0.809) for BMP10, 0.784 (95% CI, 0.765–0.810) for NT‐proBNP, and 0.789 (95% CI, 0.771–0.815) for both biomarkers combined. For MACE, the concordance index was 0.732 (95% CI, 0.715–0.754) for BMP10, 0.747 (95% CI, 0.731–0.768) for NT‐proBNP, and 0.750 (95% CI, 0.734–0.771) for both biomarkers combined. When grouping patients according to NT‐proBNP categories (<300, 300–900, >900 ng/L), higher aHRs were observed in patients with high BMP10 in the categories of low NT‐proBNP (all‐cause death aHR, 2.28 [95% CI, 1.15–4.52], MACE aHR, 1.88 [95% CI, 1.07–3.28]) and high NT‐proBNP (all‐cause death aHR, 1.61 [95% CI, 1.14–2.26], MACE aHR, 1.38 [95% CI, 1.07–1.80]). Conclusions BMP10 strongly predicted all‐cause death and MACE in patients with AF. BMP10 provided additional prognostic information in low‐ and high‐risk patients according to NT‐proBNP stratification. Registration https://www.clinicaltrials.gov ; Unique identifier: NCT02105844.
- Published
- 2023
14. Survival of turkey arthritis reovirus in poultry litter and drinking water
- Author
-
Mor, Sunil K., Verma, Harsha, Sharafeldin, Tamer A., Porter, Robert E., Ziegler, Andre F., Noll, Sally L., and Goyal, Sagar M.
- Published
- 2015
- Full Text
- View/download PDF
15. Bone Morphogenetic Protein 10-A Novel Biomarker to Predict Adverse Outcomes in Patients With Atrial Fibrillation
- Author
-
Hennings, Elisa, Blum, Steffen, Aeschbacher, Stefanie, Coslovsky, Michael, Knecht, Sven, Eken, Ceylan, Lischer, Mirko, Paladini, Rebecca E, Krisai, Philipp, Reichlin, Tobias, Rodondi, Nicolas, Beer, Jürg H, Ammann, Peter, Conte, Giulio, De Perna, Maria Luisa, Kobza, Richard, Blum, Manuel R, Bossard, Matthias, Kastner, Peter, Ziegler, André, Müller, Christian, Bonati, Leo H, Pfister, Otmar, Zuern, Christine S, Conen, David, Kühne, Michael, and Osswald, Stefan
- Subjects
360 Social problems & social services ,610 Medicine & health ,Cardiology and Cardiovascular Medicine - Abstract
Background Patients with atrial fibrillation (AF) face an increased risk of death and major adverse cardiovascular events (MACE). We aimed to assess the predictive value of the novel atrial‐specific biomarker BMP10 (bone morphogenetic protein 10) for death and MACE in patients with AF in comparison with NT‐proBNP (N‐terminal prohormone of B‐type natriuretic peptide). Methods and Results BMP10 and NT‐proBNP were measured in patients with AF enrolled in Swiss‐AF (Swiss Atrial Fibrillation Study), a prospective multicenter cohort study. A total of 2219 patients were included (median follow‐up 4.3 years [interquartile range 3.9, 5.1], mean age 73±9 years, 73% male). In multivariable Cox proportional hazard models, the adjusted hazard ratio (aHR) associated with 1 ng/mL increase of BMP10 was 1.60 (95% CI, 1.37–1.87) for all‐cause death, and 1.54 (95% CI, 1.35–1.76) for MACE. For all‐cause death, the concordance index was 0.783 (95% CI, 0.763–0.809) for BMP10, 0.784 (95% CI, 0.765–0.810) for NT‐proBNP, and 0.789 (95% CI, 0.771–0.815) for both biomarkers combined. For MACE, the concordance index was 0.732 (95% CI, 0.715–0.754) for BMP10, 0.747 (95% CI, 0.731–0.768) for NT‐proBNP, and 0.750 (95% CI, 0.734–0.771) for both biomarkers combined. When grouping patients according to NT‐proBNP categories (900 ng/L), higher aHRs were observed in patients with high BMP10 in the categories of low NT‐proBNP (all‐cause death aHR, 2.28 [95% CI, 1.15–4.52], MACE aHR, 1.88 [95% CI, 1.07–3.28]) and high NT‐proBNP (all‐cause death aHR, 1.61 [95% CI, 1.14–2.26], MACE aHR, 1.38 [95% CI, 1.07–1.80]). Conclusions BMP10 strongly predicted all‐cause death and MACE in patients with AF. BMP10 provided additional prognostic information in low‐ and high‐risk patients according to NT‐proBNP stratification. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02105844.
- Published
- 2023
- Full Text
- View/download PDF
16. Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study
- Author
-
Chua, Winnie, Law, Jonathan P., Cardoso, Victor R., Purmah, Yanish, Neculau, Georgiana, Jawad-Ul-Qamar, Muhammad, Russell, Kalisha, Turner, Ashley, Tull, Samantha P., Nehaj, Frantisek, Brady, Paul, Kastner, Peter, Ziegler, André, Gkoutos, Georgios V., Pavlovic, Davor, Ferro, Charles J., Kirchhof, Paulus, and Fabritz, Larissa
- Subjects
Diagnosis ,Models ,Development and progression ,Measurement ,Health aspects ,Atrial fibrillation -- Models -- Diagnosis -- Development and progression ,Fibroblast growth factors -- Measurement -- Health aspects ,Natriuretic peptides -- Measurement -- Health aspects ,Biological markers -- Measurement -- Health aspects - Abstract
Author(s): Winnie Chua 1, Jonathan P. Law 1,2, Victor R. Cardoso 1,3, Yanish Purmah 1,4,5, Georgiana Neculau 4,5, Muhammad Jawad-Ul-Qamar 1,4,5, Kalisha Russell 5, Ashley Turner 5, Samantha P. Tull [...], Background Large-scale screening for atrial fibrillation (AF) requires reliable methods to identify at-risk populations. Using an experimental semi-quantitative biomarker assay, B-type natriuretic peptide (BNP) and fibroblast growth factor 23 (FGF23) were recently identified as the most suitable biomarkers for detecting AF in combination with simple morphometric parameters (age, sex, and body mass index [BMI]). In this study, we validated the AF model using standardised, high-throughput, high-sensitivity biomarker assays. Methods and findings For this study, 1,625 consecutive patients with either (1) diagnosed AF or (2) sinus rhythm with CHA.sub.2 DS.sub.2 -VASc score of 2 or more were recruited from a large teaching hospital in Birmingham, West Midlands, UK, between September 2014 and February 2018. Seven-day ambulatory ECG monitoring excluded silent AF. Patients with tachyarrhythmias apart from AF and incomplete cases were excluded. AF was diagnosed according to current clinical guidelines and confirmed by ECG. We developed a high-throughput, high-sensitivity assay for FGF23, quantified plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) and FGF23, and compared results to the previously used multibiomarker research assay. Data were fitted to the previously derived model, adjusting for differences in measurement platforms and known confounders (heart failure and chronic kidney disease). In 1,084 patients (46% with AF; median [Q1, Q3] age 70 [60, 78] years, median [Q1, Q3] BMI 28.8 [25.1, 32.8] kg/m.sup.2, 59% males), patients with AF had higher concentrations of NT-proBNP (median [Q1, Q3] per 100 pg/ml: with AF 12.00 [4.19, 30.15], without AF 4.25 [1.17, 15.70]; p < 0.001) and FGF23 (median [Q1, Q3] per 100 pg/ml: with AF 1.93 [1.30, 4.16], without AF 1.55 [1.04, 2.62]; p < 0.001). Univariate associations remained after adjusting for heart failure and estimated glomerular filtration rate, known confounders of NT-proBNP and FGF23. The fitted model yielded a C-statistic of 0.688 (95% CI 0.656, 0.719), almost identical to that of the derived model (C-statistic 0.691; 95% CI 0.638, 0.744). The key limitation is that this validation was performed in a cohort that is very similar demographically to the one used in model development, calling for further external validation. Conclusions Age, sex, and BMI combined with elevated NT-proBNP and elevated FGF23, quantified on a high-throughput platform, reliably identify patients with AF. Trial registration Registry IRAS ID 97753 Health Research Authority (HRA), United Kingdom
- Published
- 2021
- Full Text
- View/download PDF
17. Characterization of S class gene segments of a newly isolated turkey arthritis reovirus
- Author
-
Mor, Sunil K., Verma, Harsha, Sharafeldin, Tamer A., Porter, Robert E., Jindal, Naresh, Ziegler, Andre, and Goyal, Sagar M.
- Published
- 2014
- Full Text
- View/download PDF
18. Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference
- Author
-
Kotecha, Dipak, Breithardt, Günter, Camm, A John, Lip, Gregory Y H, Schotten, Ulrich, Ahlsson, Anders, Arnar, David, Atar, Dan, Auricchio, Angelo, Bax, Jeroen, Benussi, Stefano, Blomstrom-Lundqvist, Carina, Borggrefe, Martin, Boriani, Giuseppe, Brandes, Axel, Calkins, Hugh, Casadei, Barbara, Castellá, Manuel, Chua, Winnie, Crijns, Harry, Dobrev, Dobromir, Fabritz, Larissa, Feuring, Martin, Freedman, Ben, Gerth, Andrea, Goette, Andreas, Guasch, Eduard, Haase, Doreen, Hatem, Stephane, Haeusler, Karl Georg, Heidbuchel, Hein, Hendriks, Jeroen, Hunter, Craig, Kääb, Stefan, Kespohl, Stefanie, Landmesser, Ulf, Lane, Deirdre A, Lewalter, Thorsten, Mont, Lluís, Nabauer, Michael, Nielsen, Jens C, Oeff, Michael, Oldgren, Jonas, Oto, Ali, Pison, Laurent, Potpara, Tatjana, Ravens, Ursula, Richard-Lordereau, Isabelle, Rienstra, Michiel, Savelieva, Irina, Schnabel, Renate, Sinner, Moritz F, Sommer, Philipp, Themistoclakis, Sakis, Van Gelder, Isabelle C, Vardas, Panagiotis E, Verma, Atul, Wakili, Reza, Weber, Evelyn, Werring, David, Willems, Stephan, Ziegler, André, Hindricks, Gerhard, and Kirchhof, Paulus
- Published
- 2018
- Full Text
- View/download PDF
19. Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
- Author
-
Hijazi, Ziad, primary, Benz, Alexander P, additional, Lindbäck, Johan, additional, Alexander, John H, additional, Connolly, Stuart J, additional, Eikelboom, John W, additional, Granger, Christopher B, additional, Kastner, Peter, additional, Lopes, Renato D, additional, Ziegler, André, additional, Oldgren, Jonas, additional, Siegbahn, Agneta, additional, and Wallentin, Lars, additional
- Published
- 2022
- Full Text
- View/download PDF
20. Isolation and Characterization of a Turkey Arthritis Reovirus
- Author
-
Mor, Sunil K., Sharafeldin, Tamer A., Porter, Robert E., Ziegler, Andre, Patnayak, Devi P., and Goyal, Sagar M.
- Published
- 2013
- Full Text
- View/download PDF
21. Association of bone morphogenetic protein 10 and recurrent atrial fibrillation after catheter ablation.
- Author
-
Hennings, Elisa, Aeschbacher, Stefanie, Coslovsky, Michael, Paladini, Rebecca E, Meyre, Pascal B, Voellmin, Gian, Blum, Livia, Kastner, Peter, Ziegler, André, Conen, David, Zuern, Christine S, Krisai, Philipp, Badertscher, Patrick, Sticherling, Christian, Osswald, Stefan, Knecht, Sven, and Kühne, Michael
- Abstract
Aims Atrial remodelling, defined as a change in atrial structure, promotes atrial fibrillation (AF). Bone morphogenetic protein 10 (BMP10) is an atrial-specific biomarker released to blood during atrial development and structural changes. We aimed to validate whether BMP10 is associated with AF recurrence after catheter ablation (CA) in a large cohort of patients. Methods and results We measured baseline BMP10 plasma concentrations in AF patients who underwent a first elective CA in the prospective Swiss-AF-PVI cohort study. The primary outcome was AF recurrence lasting longer than 30 s during a follow-up of 12 months. We constructed multivariable Cox proportional hazard models to determine the association of BMP10 and AF recurrence. A total of 1112 patients with AF (age 61 ± 10 years, 74% male, 60% paroxysmal AF) was included in our analysis. During 12 months of follow-up, 374 patients (34%) experienced AF recurrence. The probability for AF recurrence increased with increasing BMP10 concentration. In an unadjusted Cox proportional hazard model, a per-unit increase in log-transformed BMP10 was associated with a hazard ratio (HR) of 2.28 (95% CI 1.43; 3.62, P < 0.001) for AF recurrence. After multivariable adjustment, the HR of BMP10 for AF recurrence was 1.98 (95% CI 1.14; 3.42, P = 0.01), and there was a linear trend across BMP10 quartiles (P = 0.02 for linear trend). Conclusion The novel atrial-specific biomarker BMP10 was strongly associated with AF recurrence in patients undergoing CA for AF. ClinicalTrials.gov Identifier NCT03718364; https://clinicaltrials.gov/ct2/show/NCT03718364 [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. A Multiplex RT-PCR for the Detection of Astrovirus, Rotavirus, and Reovirus in Turkeys
- Author
-
Jindal, Naresh, Chander, Yogesh, Patnayak, Devi P., Mor, Sunil K., Ziegler, Andre F., and Goyal, Sagar M.
- Published
- 2012
23. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference
- Author
-
Schnabel, Renate B, primary, Marinelli, Elena Andreassi, additional, Arbelo, Elena, additional, Boriani, Giuseppe, additional, Boveda, Serge, additional, Buckley, Claire M, additional, Camm, A John, additional, Casadei, Barbara, additional, Chua, Winnie, additional, Dagres, Nikolaos, additional, de Melis, Mirko, additional, Desteghe, Lien, additional, Diederichsen, Søren Zöga, additional, Duncker, David, additional, Eckardt, Lars, additional, Eisert, Christoph, additional, Engler, Daniel, additional, Fabritz, Larissa, additional, Freedman, Ben, additional, Gillet, Ludovic, additional, Goette, Andreas, additional, Guasch, Eduard, additional, Svendsen, Jesper Hastrup, additional, Hatem, Stéphane N, additional, Haeusler, Karl Georg, additional, Healey, Jeff S, additional, Heidbuchel, Hein, additional, Hindricks, Gerhard, additional, Hobbs, F D Richard, additional, Hübner, Thomas, additional, Kotecha, Dipak, additional, Krekler, Michael, additional, Leclercq, Christophe, additional, Lewalter, Thorsten, additional, Lin, Honghuang, additional, Linz, Dominik, additional, Lip, Gregory Y H, additional, Løchen, Maja Lisa, additional, Lucassen, Wim, additional, Malaczynska-Rajpold, Katarzyna, additional, Massberg, Steffen, additional, Merino, Jose L, additional, Meyer, Ralf, additional, Mont, Lluıs, additional, Myers, Michael C, additional, Neubeck, Lis, additional, Niiranen, Teemu, additional, Oeff, Michael, additional, Oldgren, Jonas, additional, Potpara, Tatjana S, additional, Psaroudakis, George, additional, Pürerfellner, Helmut, additional, Ravens, Ursula, additional, Rienstra, Michiel, additional, Rivard, Lena, additional, Scherr, Daniel, additional, Schotten, Ulrich, additional, Shah, Dipen, additional, Sinner, Moritz F, additional, Smolnik, Rüdiger, additional, Steinbeck, Gerhard, additional, Steven, Daniel, additional, Svennberg, Emma, additional, Thomas, Dierk, additional, True Hills, Mellanie, additional, van Gelder, Isabelle C, additional, Vardar, Burcu, additional, Palà, Elena, additional, Wakili, Reza, additional, Wegscheider, Karl, additional, Wieloch, Mattias, additional, Willems, Stephan, additional, Witt, Henning, additional, Ziegler, André, additional, Daniel Zink, Matthias, additional, and Kirchhof, Paulus, additional
- Published
- 2022
- Full Text
- View/download PDF
24. Duration of Growth Depression and Pathogen Shedding in Experimentally Reproduced Poult Enteritis Syndrome
- Author
-
Jindal, Naresh, Patnayak, Devi P., Ziegler, Andre F., Lago, Alfonso, and Goyal, Sagar M.
- Published
- 2009
25. A Retrospective Study on Poult Enteritis Syndrome in Minnesota
- Author
-
Jindal, Naresh, Patnayak, Devi P., Ziegler, Andre F., Lago, Alfonso, and Goyal, Sagar M.
- Published
- 2009
26. Bone morphogenetic protein 10 : a novel risk marker of ischaemic stroke in patients with atrial fibrillation
- Author
-
Hijazi, Ziad, Benz, Alexander P., Lindbäck, Johan, Alexander, John H., Connolly, Stuart J., Eikelboom, John W., Granger, Christopher B., Kastner, Peter, Lopes, Renato D., Ziegler, André, Oldgren, Jonas, Siegbahn, Agneta, Wallentin, Lars, Hijazi, Ziad, Benz, Alexander P., Lindbäck, Johan, Alexander, John H., Connolly, Stuart J., Eikelboom, John W., Granger, Christopher B., Kastner, Peter, Lopes, Renato D., Ziegler, André, Oldgren, Jonas, Siegbahn, Agneta, and Wallentin, Lars
- Abstract
AIMS: Biomarkers specifically related to atrial tissue may increase the understanding of the pathophysiology of atrial fibrillation (AF) and further improve risk prediction in this setting. Bone morphogenetic protein 10 (BMP10) is a protein expressed in the atrial myocardium. We evaluated the association between BMP10 and the risk of ischaemic stroke and other cardiovascular events in large cohorts of patients with AF, treated with and without oral anticoagulation (OAC). METHODS AND RESULTS: BMP10 was measured in plasma samples collected at randomisation in patients with AF without OAC in the ACTIVE A and AVERROES trials (n = 2974), and with OAC in the ARISTOTLE trial (n = 13 079). BMP10 was analysed with a prototype Elecsys immunoassay. Associations with outcomes were evaluated by Cox-regression models adjusted for clinical characteristics, kidney function, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Median concentrations of BMP10 were 2.47 and 2.44 ng/mL, in the non-OAC and OAC cohort, respectively. Increasing BMP10 was associated with lower body mass index, older age, female sex, kidney dysfunction, and AF rhythm. BMP10 was consistently associated with ischaemic stroke. In the non-OAC cohort, BMP10 increased the concordance index of the multivariable model from 0.713 to 0.733 (P = 0.004) and in the OAC cohort from 0.673 to 0.694 (P < 0.001). Additionally, BMP10 maintained a significant prognostic value after additionally adjusting for NT-proBNP. BMP10 was not independently associated with bleeding or with death. CONCLUSION: The novel atrial biomarker BMP10 was independently associated with ischaemic stroke in patients with AF irrespective of OAC treatment. BMP10 seems to be more specifically related to the risk of ischaemic stroke in AF. ONE-SENTENCE SUMMARY: In this study, BMP10 may be a novel specific biomarker of ischaemic stroke in patients with atrial fibrillation, irrespective of oral anticoagulation.
- Published
- 2022
- Full Text
- View/download PDF
27. Cardiovascular disease in the elderly: proceedings of the European Society of Cardiology - Cardiovascular Round Table
- Author
-
Interne Geneeskunde Vasculaire, Circulatory Health, Lettino, Maddalena, Mascherbauer, Julia, Nordaby, Matias, Ziegler, André, Collet, Jean Philippe, Derumeaux, Geneviève, Hohnloser, Stefan H., Leclercq, Christophe, O'neill, Deirdre E., Visseren, Frank, Weidinger, Franz, Richard-Lordereau, Isabelle, Interne Geneeskunde Vasculaire, Circulatory Health, Lettino, Maddalena, Mascherbauer, Julia, Nordaby, Matias, Ziegler, André, Collet, Jean Philippe, Derumeaux, Geneviève, Hohnloser, Stefan H., Leclercq, Christophe, O'neill, Deirdre E., Visseren, Frank, Weidinger, Franz, and Richard-Lordereau, Isabelle
- Published
- 2022
28. Nebulosa autoficcional : hesitações e [trans] midiatizações poéticas visuais
- Author
-
Ziegler, André Martins, Medeiros, Rosângela Fachel de, and Castellani, Felipe Merker
- Subjects
narrative ,autoficção ,LINGUISTICA, LETRAS E ARTES::ARTES [CNPQ] ,queer ,visual-poetics ,autofiction ,transmídia ,narrativa ,Poéticas-visuais ,transmedia - Abstract
Submitted by Leda Lopes (ledacplopes@hotmail.com) on 2022-03-18T13:19:43Z No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) André_Martins_Dissertação.pdf: 19966743 bytes, checksum: 79b5c9bacae81122e8909c3b5f9b02b6 (MD5) Approved for entry into archive by Aline Batista (alinehb.ufpel@gmail.com) on 2022-03-18T22:00:13Z (GMT) No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) André_Martins_Dissertação.pdf: 19966743 bytes, checksum: 79b5c9bacae81122e8909c3b5f9b02b6 (MD5) Made available in DSpace on 2022-03-18T22:00:13Z (GMT). No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) André_Martins_Dissertação.pdf: 19966743 bytes, checksum: 79b5c9bacae81122e8909c3b5f9b02b6 (MD5) Previous issue date: 2021-12-16 Nesta dissertação apresento meu processo de investigação/criação poética-artística autoficcional e transmidiática por meio de uma metodologia de múltiplas análises e revisões. Inicialmente, busco delinear três aspectos do termo autoficção: a “autonálise”, a “narrativa textual” e o “pacto oximórico”. Para, em seguida, pensar a autoficção enquanto uma mutação cultural desencadeadora de práticas autoficcionais únicas para cada pessoa que narra sobre si-mesma, diante das diversas circunstâncias artísticas, tecnológicas, políticas, industriais, estéticas e sociais em intersecção aos hypes e trends publicitários, analisando a partir disto a transmídia como um quarto aspecto herdado em minhas práticas autoficcionais. Em paralelo à revisão e apropriação teórica reflito sobre meus processos de criação quimérica em artes digitais, que mesclam estéticas inspiradas em filmes, fotografias e imagens de cunho fantástico e conceitual, bem como em movimentos artísticos, como o surrealismo, o vaporwave, a glitch art e o aesthetic. Por uma escrita permeada por justo desvios, imbrico narrativas literárias autofabulativas fantásticas com as discussões dissertativas, integrando afetos e lembranças no processo investigativo que me fazem refletir sobre uma noção de minha existência circunstanciada por uma corporeidade “fragmentanda”, por conta das subjetividades e burocratizações urbanísticas-capitalistas que categorizam e segregam as diversas formas de vida. Nas considerações finais ponho em percepção que as minhas poéticas visuais se fazem enquanto vias de acesso aos estados de hesitações que possibilitam redistribuir dialéticas de ficções que constituem uma noção de realidade e uma experiência de queerização. A escrita pela ideia de uma nebulosa em expansão é pensada enquanto uma experiência em vivência que constitui a própria dissertação, pondo em reflexão sobre a metodologia e estrutura de narrativa de uma pesquisa poética no campo das artes que mescla cientificidade e ficção . I present in this dissertation my process of autofictional and transmediatic poetic-artistic investigation through a methodology of multiple analyses and reviews. Initially, I seek to delineate three aspects of the term autofiction: the "autonalysis", the "textual narrative" and the "oxymoronic pact". To then think of autofiction as a cultural mutation triggering autofictional practices unique to each person who narrates about themselves, given the context of diverse artistic, technological, political, industrial, aesthetic, and social circumstances in intersection with hypes and trends, bringing transmedia as a fourth aspect of my autofictions practices. Concomitant to the theoretical review and appropriation, I reflect on my chimerical processes creation in digital arts, which blend aesthetics inspired by fantastic and conceptual films, photographs, and images, as well as by artistic movements, such as surrealism, and by vaporwave, glitch art, and the aesthetics of cyberculture. Through a writing permeated by fair deviations, I interweave fantastic autofabulous literary narratives with the dissertation discussions, integrating affections and memories in the investigative process that make me reflect on a notion of my existence circumscribed by a "fragmented" corporeality, due to subjectivities and urban-capitalist bureaucratizations that categorize and segregate the diverse forms of life. In the final considerations, I realize that my visual poetics are ways to acess states of hesitations that make it possible to redistribute dialectics of fictions that constitute a notion of reality and an experience of queerization. The writing by the idea of an expanding nebula is thought of as an experience in living that constitutes the dissertation itself, reflecting on the methodology and narrative structure of a poetic research in the field of arts that hybridizes science and fiction.
- Published
- 2021
29. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference
- Author
-
Kirchhof, Paulus, Breithardt, Günter, Bax, Jeroen, Benninger, Gerlinde, Blomstrom-Lundqvist, Carina, Boriani, Giuseppe, Brandes, Axel, Brown, Helen, Brueckmann, Martina, Calkins, Hugh, Calvert, Melanie, Christoffels, Vincent, Crijns, Harry, Dobrev, Dobromir, Ellinor, Patrick, Fabritz, Larissa, Fetsch, Thomas, Freedman, S. Ben, Gerth, Andrea, Goette, Andreas, Guasch, Eduard, Hack, Guido, Haegeli, Laurent, Hatem, Stephane, Haeusler, Karl Georg, Heidbüchel, Hein, Heinrich-Nols, Jutta, Hidden-Lucet, Francoise, Hindricks, Gerd, Juul-Möller, Steen, Kääb, Stefan, Kappenberger, Lukas, Kespohl, Stefanie, Kotecha, Dipak, Lane, Deirdre A., Leute, Angelika, Lewalter, Thorsten, Meyer, Ralf, Mont, Lluis, Münzel, Felix, Nabauer, Michael, Nielsen, Jens C., Oeff, Michael, Oldgren, Jonas, Oto, Ali, Piccini, Jonathan P., Pilmeyer, Art, Potpara, Tatjana, Ravens, Ursula, Reinecke, Holger, Rostock, Thomas, Rustige, Joerg, Savelieva, Irene, Schnabel, Renate, Schotten, Ulrich, Schwichtenberg, Lars, Sinner, Moritz F., Steinbeck, Gerhard, Stoll, Monika, Tavazzi, Luigi, Themistoclakis, Sakis, Tse, Hung Fat, Van Gelder, Isabelle C., Vardas, Panagiotis E., Varpula, Timo, Vincent, Alphons, Werring, David, Willems, Stephan, Ziegler, André, Lip, Gregory Y.H., and Camm, A. John
- Published
- 2016
- Full Text
- View/download PDF
30. Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation.
- Author
-
Hijazi, Ziad, Benz, Alexander P, Lindbäck, Johan, Alexander, John H, Connolly, Stuart J, Eikelboom, John W, Granger, Christopher B, Kastner, Peter, Lopes, Renato D, Ziegler, André, Oldgren, Jonas, Siegbahn, Agneta, and Wallentin, Lars
- Subjects
BONE morphogenetic proteins ,ISCHEMIC stroke ,ATRIAL fibrillation ,STROKE patients ,HEART atrium ,BODY mass index - Abstract
Aims Biomarkers specifically related to atrial tissue may increase the understanding of the pathophysiology of atrial fibrillation (AF) and further improve risk prediction in this setting. Bone morphogenetic protein 10 (BMP10) is a protein expressed in the atrial myocardium. We evaluated the association between BMP10 and the risk of ischaemic stroke and other cardiovascular events in large cohorts of patients with AF, treated with and without oral anticoagulation (OAC). Methods and results BMP10 was measured in plasma samples collected at randomisation in patients with AF without OAC in the ACTIVE A and AVERROES trials (n = 2974), and with OAC in the ARISTOTLE trial (n = 13 079). BMP10 was analysed with a prototype Elecsys immunoassay. Associations with outcomes were evaluated by Cox-regression models adjusted for clinical characteristics, kidney function, and N -terminal pro-B-type natriuretic peptide (NT-proBNP). Median concentrations of BMP10 were 2.47 and 2.44 ng/mL, in the non-OAC and OAC cohort, respectively. Increasing BMP10 was associated with lower body mass index, older age, female sex, kidney dysfunction, and AF rhythm. BMP10 was consistently associated with ischaemic stroke. In the non-OAC cohort, BMP10 increased the concordance index of the multivariable model from 0.713 to 0.733 (P = 0.004) and in the OAC cohort from 0.673 to 0.694 (P < 0.001). Additionally, BMP10 maintained a significant prognostic value after additionally adjusting for NT-proBNP. BMP10 was not independently associated with bleeding or with death. Conclusion The novel atrial biomarker BMP10 was independently associated with ischaemic stroke in patients with AF irrespective of OAC treatment. BMP10 seems to be more specifically related to the risk of ischaemic stroke in AF. One-sentence Summary In this study, BMP10 may be a novel specific biomarker of ischaemic stroke in patients with atrial fibrillation, irrespective of oral anticoagulation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Binding and Clustering of Glycosaminoglycans: A Common Property of Mono- and Multivalent Cell-Penetrating Compounds
- Author
-
Ziegler, André and Seelig, Joachim
- Published
- 2008
- Full Text
- View/download PDF
32. POÉTICA DA AUTOFICÇÃO NA PERSPECTIVA YIN YANG E UMA MICROCULTURA DIALÉTICA E HOLÍSTICA DO CORPO
- Author
-
Ziegler, André Martins, primary
- Published
- 2021
- Full Text
- View/download PDF
33. Development, validation and implementation of biomarker testing in cardiovascular medicine state-of-the-art : Proceedings of the European Society of Cardiology - Cardiovascular Round Table
- Author
-
Elliott, Perry, Cowie, Martin R., Franke, Jennifer, Ziegler, André, Antoniades, Charalambos, Bax, Jeroen, Bucciarelli-Ducci, Chiara, Flachskampf, Frank A., Hamm, Christian, Jensen, Magnus T., Katus, Hugo, Maisel, Alan, McDonagh, Theresa, Mittmann, Clemens, Muntendam, Pieter, Nagel, Eike, Rosano, Giuseppe, Twerenbold, Raphael, Zannad, Faiez, Elliott, Perry, Cowie, Martin R., Franke, Jennifer, Ziegler, André, Antoniades, Charalambos, Bax, Jeroen, Bucciarelli-Ducci, Chiara, Flachskampf, Frank A., Hamm, Christian, Jensen, Magnus T., Katus, Hugo, Maisel, Alan, McDonagh, Theresa, Mittmann, Clemens, Muntendam, Pieter, Nagel, Eike, Rosano, Giuseppe, Twerenbold, Raphael, and Zannad, Faiez
- Abstract
Many biomarkers that could be used to assess ejection fraction, heart failure, or myocardial infarction fail to translate into clinical practice because they lack essential performance characteristics or fail to meet regulatory standards for approval. Despite their potential, new technologies have added to the complexities of successful translation into clinical practice. Biomarker discovery and implementation requires a standardised approach that includes: identification of a clinical need; identification of a valid surrogate biomarker; stepwise assay refinement, demonstration of superiority over current standard-of-care; development and understanding of a clinical pathway; and demonstration of real-world performance. Successful biomarkers should improve efficacy or safety of treatment, while being practical at a realistic cost. Everyone involved in cardiovascular healthcare, including researchers, clinicians, and industry partners, are important stakeholders in facilitating the development and implementation of biomarkers. This paper provides suggestions for a development pathway for new biomarkers, discusses regulatory issues and challenges, and suggestions for accelerating the pathway to improve patient outcomes. Real life examples of successful biomarkers-high sensitivity cardiac troponin (hs-cTn), T2* cardiovascular magnetic resonance (CMR) imaging, and echocardiography-are used to illustrate the value of a standardised development pathway in the translation of concepts into routine clinical practice.
- Published
- 2021
- Full Text
- View/download PDF
34. Development, validation, and implementation of biomarker testing in cardiovascular medicine state-of-the-art: proceedings of the European Society of Cardiology—Cardiovascular Round Table
- Author
-
Elliott, Perry, primary, Cowie, Martin R, additional, Franke, Jennifer, additional, Ziegler, André, additional, Antoniades, Charalambos, additional, Bax, Jeroen, additional, Bucciarelli-Ducci, Chiara, additional, Flachskampf, Frank A, additional, Hamm, Christian, additional, Jensen, Magnus T, additional, Katus, Hugo, additional, Maisel, Alan, additional, McDonagh, Theresa, additional, Mittmann, Clemens, additional, Muntendam, Pieter, additional, Nagel, Eike, additional, Rosano, Giuseppe, additional, Twerenbold, Raphael, additional, and Zannad, Faiez, additional
- Published
- 2020
- Full Text
- View/download PDF
35. Using Sex‐specific Cutoffs for High‐sensitivity Cardiac Troponin T to Diagnose Acute Myocardial Infarction
- Author
-
Peacock, W. Frank, primary, Baumann, Brigitte M., additional, Rivers, E. Joy, additional, Davis, Thomas E., additional, Handy, Beverly, additional, Jones, Christopher W., additional, Hollander, Judd E., additional, Limkakeng, Alexander T., additional, Mehrotra, Abhi, additional, Than, Martin, additional, Cullen, Louise, additional, Ziegler, André, additional, and Dinkel‐Keuthage, Carina, additional
- Published
- 2020
- Full Text
- View/download PDF
36. Interaction of the Protein Transduction Domain of HIV-1 TAT with Heparan Sulfate: Binding Mechanism and Thermodynamic Parameters
- Author
-
Ziegler, André and Seelig, Joachim
- Published
- 2004
- Full Text
- View/download PDF
37. Thermodynamics of Sodium Dodecyl Sulfate Partitioning into Lipid Membranes
- Author
-
Tan, Anmin, Ziegler, André, Steinbauer, Bernhard, and Seelig, Joachim
- Published
- 2002
- Full Text
- View/download PDF
38. Using Sex‐specific Cutoffs for High‐sensitivity Cardiac Troponin T to Diagnose Acute Myocardial Infarction.
- Author
-
Peacock, W. Frank, Baumann, Brigitte M., Rivers, E. Joy, Davis, Thomas E., Handy, Beverly, Jones, Christopher W., Hollander, Judd E., Limkakeng, Alexander T., Mehrotra, Abhi, Than, Martin, Cullen, Louise, Ziegler, André, Dinkel‐Keuthage, Carina, and Diercks, Deborah B.
- Subjects
MYOCARDIAL infarction diagnosis ,REFERENCE values ,TROPONIN ,BIOMARKERS ,RESEARCH ,MYOCARDIAL infarction ,SEX distribution ,DESCRIPTIVE statistics ,DATA analysis software ,ACUTE diseases - Abstract
The article focuses on high-sensitivity cardiac troponin (hs-cTn) assays facilitate early decision making in acute myocardial infarction and the accuracy of these assays allow sex-specific differences in levels to be detected within healthy populations. Topics include the differences in plasma levels of cardiac troponin are due to sex-specific variations in body composition and cardiac physiology, and the women presenting with suspected acute coronary syndrome are less frequently diagnosed.
- Published
- 2021
- Full Text
- View/download PDF
39. Antiarrhythmic effect of ischemic preconditioning during low-flow ischemia: The role of bradykinin and sarcolemmal versus mitochondrial ATP-sensitive K+ channels
- Author
-
Driamov, Sergey, Bellahcene, Mohamed, Ziegler, André, Barbosa, Vânia, Traub, David, Butz, Silvia, Buser, Peter, Zaugg, Christian, Driamov, Sergey, Bellahcene, Mohamed, Ziegler, André, Barbosa, Vânia, Traub, David, Butz, Silvia, Buser, Peter, and Zaugg, Christian
- Abstract
: Short episodes of ischemia (ischemic preconditioning) protect the heart against ventricular arrhythmias during zero-flow ischemia and reperfusion. However, in clinics, many episodes of ischemia present a residual flow (low-flow ischemia). Here we examined whether ischemic preconditioning protects against ventricular arrhythmias during and after a low-flow ischemia and, if so, by what mechanism(s). Isolated rat hearts were subjected to 60 min of low-flow ischemia (12% residual coronary flow) followed by 60 min of reperfusion. Ischemic preconditioning was induced by two cycles of 5 min of zero-flow ischemia followed by 5 and 15 min of reperfusion, respectively. Arrhythmias were evaluated as numbers of ventricular premature beats (VPBs) as well as incidences of ventricular tachycardia (VT) and ventricular .brillation (VF) during low-flow ischemia and reperfusion. Ischemic preconditioning significantly reduced the number of VPBs and the incidence of VT and of VF during low-flow ischemia. This antiarrhythmic effect of preconditioning was abolished by HOE 140 (100 nM), a bradykinin B2 receptor blocker. Similar to preconditioning, exogenous bradykinin (10 nM) reduced the number of VPBs and the incidence of VT and of VF during low-flow ischemia. Furthermore, the antiarrhythmic effects of both ischemic preconditioning and bradykinin were abolished by glibenclamide (1 µM), a non-specific blocker of ATP-sensitive K+ (KATP) channels. Finally, the antiarrhythmic effects of both ischemic preconditioning and bradykinin were abolished by HMR 1098 (10 µM), a sarcolemmal KATP channel blocker but not by 5-hydroxydecanoate (100 µM), a mitochondrial KATP channel blocker. In conclusion, ischemic preconditioning protects against ventricular arrhythmias induced by low-flow ischemia, and this protection involves activation of bradykinin B2 receptors and subsequent opening of sarcolemmal but not of mitochondrial KATP channels
- Published
- 2018
40. A roadmap to improve the quality of atrial fibrillation managementconference : proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus
- Author
-
Kirchhof, Paulus, Breithardt, Günter, Bax, Jeroen, Benninger, Gerlinde, Blomstrom-Lundqvist, Carina, Boriani, Giuseppe, Brandes, Axel, Brown, Helen, Brueckmann, Martina, Calkins, Hugh, Calvert, Melanie, Christoffels, Vincent, Crijns, Harry, Dobrev, Dobromir, Ellinor, Patrick, Fabritz, Larissa, Fetsch, Thomas, Freedman, S. Ben, Gerth, Andrea, Goette, Andreas, Guasch, Eduard, Hack, Guido, Haegeli, Laurent, Hatem, Stephane, Haeusler, Karl Georg, Heidbüchel, Hein, Heinrich-Nols, Jutta, Hidden-Lucet, Francoise, Hindricks, Gerd, Juul-Möller, Steen, Kääb, Stefan, Kappenberger, Lukas, Kespohl, Stefanie, Kotecha, Dipak, Lane, Deirdre A., Leute, Angelika, Lewalter, Thorsten, Meyer, Ralf, Mont, Lluis, Münzel, Felix, Nabauer, Michael, Nielsen, Jens C., Oeff, Michael, Oldgren, Jonas, Oto, Ali, Piccini, Jonathan P., Pilmeyer, Art, Potpara, Tatjana, Ravens, Ursula, Reinecke, Holger, Rostock, Thomas, Rustige, Joerg, Savelieva, Irene, Schnabel, Renate, Schotten, Ulrich, Schwichtenberg, Lars, Sinner, Moritz F., Steinbeck, Gerhard, Stoll, Monika, Tavazzi, Luigi, Themistoclakis, Sakis, Tse, Hung Fat, van Gelder, Isabelle C., Vardas, Panagiotis E., Varpula, Timo, Vincent, Alphons, Werring, David, Willems, Stephan, Ziegler, André, Lip, Gregory Y. H., and Camm, A. John
- Subjects
Medizin - Abstract
OA embargo
- Published
- 2016
41. Early diagnosis of acute coronary syndrome
- Author
-
Katus, Hugo, primary, Ziegler, André, additional, Ekinci, Okan, additional, Giannitsis, Evangelos, additional, Stough, Wendy Gattis, additional, Achenbach, Stephan, additional, Blankenberg, Stefan, additional, Brueckmann, Martina, additional, Collinson, Paul, additional, Comaniciu, Dorin, additional, Crea, Filippo, additional, Dinh, Wilfried, additional, Ducrocq, Grégory, additional, Flachskampf, Frank A., additional, Fox, Keith A. A., additional, Friedrich, Matthias G., additional, Hebert, Kathy A., additional, Himmelmann, Anders, additional, Hlatky, Mark, additional, Lautsch, Dominik, additional, Lindahl, Bertil, additional, Lindholm, Daniel, additional, Mills, Nicholas L., additional, Minotti, Giorgio, additional, Möckel, Martin, additional, Omland, Torbjørn, additional, and Semjonow, Véronique, additional
- Published
- 2017
- Full Text
- View/download PDF
42. O ESPELHO DE OJESED NO MUNDO DOS TROUXAS.
- Author
-
Martins Ziegler, André
- Subjects
ESSAYISTS ,PHILOSOPHERS ,MIRRORS ,SENSORY perception ,ANALOGY - Abstract
Copyright of Pixo: Revista de Arquitetura Cidade e Contemporaneidade is the property of Pixo Revista de Arquitetura Cidade e Contemporaneidade and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
43. Early diagnosis of acute coronary syndrome
- Author
-
Katus, Hugo, Ziegler, André, Ekinci, Okan, Giannitsis, Evangelos, Stough, Wendy Gattis, Achenbach, Stephan, Blankenberg, Stefan, Brueckmann, Martina, Collinson, Paul, Comaniciu, Dorin, Crea, Filippo, Dinh, Wilfried, Ducrocq, Grégory, Flachskampf, Frank A., Fox, Keith A A, Friedrich, Matthias G, Hebert, Kathy A, Himmelmann, Anders, Hlatky, Mark, Lautsch, Dominik, Lindahl, Bertil, Lindholm, Daniel, Mills, Nicholas L, Minotti, Giorgio, Möckel, Martin, Omland, Torbjørn, Semjonow, Véronique, Katus, Hugo, Ziegler, André, Ekinci, Okan, Giannitsis, Evangelos, Stough, Wendy Gattis, Achenbach, Stephan, Blankenberg, Stefan, Brueckmann, Martina, Collinson, Paul, Comaniciu, Dorin, Crea, Filippo, Dinh, Wilfried, Ducrocq, Grégory, Flachskampf, Frank A., Fox, Keith A A, Friedrich, Matthias G, Hebert, Kathy A, Himmelmann, Anders, Hlatky, Mark, Lautsch, Dominik, Lindahl, Bertil, Lindholm, Daniel, Mills, Nicholas L, Minotti, Giorgio, Möckel, Martin, Omland, Torbjørn, and Semjonow, Véronique
- Abstract
The diagnostic evaluation of acute chest pain has been augmented in recent years by advances in the sensitivity and precision of cardiac troponin assays, new biomarkers, improvements in imaging modalities, and release of new clinical decision algorithms. This progress has enabled physicians to diagnose or rule-out acute myocardial infarction earlier after the initial patient presentation, usually in emergency department settings, which may facilitate prompt initiation of evidence-based treatments, investigation of alternative diagnoses for chest pain, or discharge, and permit better utilization of healthcare resources. A non-trivial proportion of patients fall in an indeterminate category according to rule-out algorithms, and minimal evidence-based guidance exists for the optimal evaluation, monitoring, and treatment of these patients. The Cardiovascular Round Table of the ESC proposes approaches for the optimal application of early strategies in clinical practice to improve patient care following the review of recent advances in the early diagnosis of acute coronary syndrome. The following specific 'indeterminate' patient categories were considered: (i) patients with symptoms and high-sensitivity cardiac troponin <99th percentile; (ii) patients with symptoms and high-sensitivity troponin <99th percentile but above the limit of detection; (iii) patients with symptoms and high-sensitivity troponin >99th percentile but without dynamic change; and (iv) patients with symptoms and high-sensitivity troponin >99th percentile and dynamic change but without coronary plaque rupture/erosion/dissection. Definitive evidence is currently lacking to manage these patients whose early diagnosis is 'indeterminate' and these areas of uncertainty should be assigned a high priority for research.
- Published
- 2017
- Full Text
- View/download PDF
44. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference
- Author
-
Kirchhof, Paulus, primary, Breithardt, Günter, additional, Bax, Jeroen, additional, Benninger, Gerlinde, additional, Blomstrom-Lundqvist, Carina, additional, Boriani, Giuseppe, additional, Brandes, Axel, additional, Brown, Helen, additional, Brueckmann, Martina, additional, Calkins, Hugh, additional, Calvert, Melanie, additional, Christoffels, Vincent, additional, Crijns, Harry, additional, Dobrev, Dobromir, additional, Ellinor, Patrick, additional, Fabritz, Larissa, additional, Fetsch, Thomas, additional, Freedman, S. Ben, additional, Gerth, Andrea, additional, Goette, Andreas, additional, Guasch, Eduard, additional, Hack, Guido, additional, Haegeli, Laurent, additional, Hatem, Stephane, additional, Haeusler, Karl Georg, additional, Heidbüchel, Hein, additional, Heinrich-Nols, Jutta, additional, Hidden-Lucet, Francoise, additional, Hindricks, Gerd, additional, Juul-Möller, Steen, additional, Kääb, Stefan, additional, Kappenberger, Lukas, additional, Kespohl, Stefanie, additional, Kotecha, Dipak, additional, Lane, Deirdre A., additional, Leute, Angelika, additional, Lewalter, Thorsten, additional, Meyer, Ralf, additional, Mont, Lluis, additional, Münzel, Felix, additional, Nabauer, Michael, additional, Nielsen, Jens C., additional, Oeff, Michael, additional, Oldgren, Jonas, additional, Oto, Ali, additional, Piccini, Jonathan P., additional, Pilmeyer, Art, additional, Potpara, Tatjana, additional, Ravens, Ursula, additional, Reinecke, Holger, additional, Rostock, Thomas, additional, Rustige, Joerg, additional, Savelieva, Irene, additional, Schnabel, Renate, additional, Schotten, Ulrich, additional, Schwichtenberg, Lars, additional, Sinner, Moritz F., additional, Steinbeck, Gerhard, additional, Stoll, Monika, additional, Tavazzi, Luigi, additional, Themistoclakis, Sakis, additional, Tse, Hung Fat, additional, Van Gelder, Isabelle C., additional, Vardas, Panagiotis E., additional, Varpula, Timo, additional, Vincent, Alphons, additional, Werring, David, additional, Willems, Stephan, additional, Ziegler, André, additional, Lip, Gregory Y.H., additional, and Camm, A. John, additional
- Published
- 2015
- Full Text
- View/download PDF
45. Troponin Testing for Detection of Acute Myocardial Infarction in Skeletal Muscle Disease Patients
- Author
-
Ziegler, André, primary, Menassanch-Volker, Sylvie, additional, and Zaugg, Christian, additional
- Published
- 2013
- Full Text
- View/download PDF
46. Implications of adjustment of high-sensitivity cardiac troponin T assay
- Author
-
Hallermayer, Klaus, primary, Jarausch, Jochen, primary, Menassanch-Volker, Sylvie, primary, Zaugg, Christian, primary, and Ziegler, André, primary
- Published
- 2013
- Full Text
- View/download PDF
47. Cell Penetrating Peptides. How do they Cross Membranes?
- Author
-
Seelig, Joachim, primary, Ziegler, André, additional, and Klocek, Gabriela, additional
- Published
- 2011
- Full Text
- View/download PDF
48. Thermodynamics of Protein Self-Association and Unfolding. The Case of Apolipoprotein A-I
- Author
-
Zehender, Fabian, Ziegler, Andre, Schoenfeld, Hans-Joachim, and Seelig, Joachim
- Published
- 2012
- Full Text
- View/download PDF
49. Early Diagnosis and Better Rhythm Management to improve outcomes in patients with Atrial Fibrillation: The 8th AFNET/EHRA Consensus Conference
- Author
-
Guiseppe, Boriani, Diederichsen, Søren, Eisert, Christoph, Schnabel, Renate B., Andreassi Marinelli, Elena, Arbelo, Elena, Boveda, Serge, Buckley, Claire, Camm, A. John, Casadei, Barbara, Chua, Winnie, Dagres, Nikolaos, de Melis, Mirko, Desteghe, Lien, Diederichsen, Søren Zöga, Duncker, David, Eckardt, Lars, Engler, Daniel, Fabritz, Larissa, Freedman, Ben, Gillet, Ludovic, Götte, Andreas, Guasch, Eduard, Hastrup Svendsen, Jesper, Hatem, Stéphane, Häusler, Karl Georg, Healey, Jeff S., Heidbüchel, Hein, Hindricks, Gerhard, Hobbs, Richard, Hübner, Thomas, Kotecha, Dipak, Krekler, Michael, Leclercq, Christophe, Lewalter, Thorsten, Lin, Honghuang, Linz, Dominik, Lip, Gregory Y. H, Løchen, Maja-Lisa, Lucassen, Wim, Malaczynska-Rajpold, Katarzyna, Massberg, Steffen, Merino, José L., Meyer, Ralf, Mont, Lluis, Myers, Michael, Neubeck, Lis, Niiranen, Temu, Oeff, Michael, Oldgren, Jonas, Potpara, Tatjana S., Psaroudakis, Georg, Pürerfellner, Helmut, Ravens, Ursula, Rienstra, Michiel, Rivard, Lena, Scherr, Daniel, Schotten, Ulrich, Shah, Dipen, Sinner, Moritz F., Smolnik, Rüdiger, Steinbeck, Gerhard, Steven, Daniel, Svennberg, Emma, Thomas, Dierk, True Hills, Mellanie, van Gelder, Isabelle C., Vardar, Burcu, Vila Pala, Elena, Wakili, Reza, Wegscheider, Karl, Wieloch, Mattias, Willems, Stephan, Witt, Henning, Ziegler, André, Zink, Matthias, and Kirchhof, Paulus
- Subjects
Artificial intelligence ,Technology ,Cost ,Research ,Bleeding ,Quality of care ,Heart failure ,Outcomes ,Atrial fibrillation ,Anticoagulation ,Dementia ,Catheter ablation ,Cognitive function ,Rhythm management ,Atrial cardiomyopathy ,Research priorities - Abstract
AimsDespite marked progress in the management of atrial fibrillation (AF), detecting AF remains difficult and AF-related complications cause unacceptable morbidity and mortality even on optimal current therapy.Methods and resultsThis document summarizes the key outcomes of the 8th AFNET/EHRA Consensus Conference of the Atrial Fibrillation NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eighty-three international experts met in Hamburg for 2 days in October 2021. Results of the interdisciplinary, hybrid discussions in breakout groups and the plenary based on recently published and unpublished observations are summarized in this consensus paper to support improved care for patients with AF by guiding prevention, individualized management, and research strategies. The main outcomes are (i) new evidence supports a simple, scalable, and pragmatic population-based AF screening pathway; (ii) rhythm management is evolving from therapy aimed at improving symptoms to an integrated domain in the prevention of AF-related outcomes, especially in patients with recently diagnosed AF; (iii) improved characterization of atrial cardiomyopathy may help to identify patients in need for therapy; (iv) standardized assessment of cognitive function in patients with AF could lead to improvement in patient outcomes; and (v) artificial intelligence (AI) can support all of the above aims, but requires advanced interdisciplinary knowledge and collaboration as well as a better medico-legal framework.ConclusionsImplementation of new evidence-based approaches to AF screening and rhythm management can improve outcomes in patients with AF. Additional benefits are possible with further efforts to identify and target atrial cardiomyopathy and cognitive impairment, which can be facilitated by AI.
50. Antiarrhythmic effect of ischemic preconditioning during low-flow ischemia: The role of bradykinin and sarcolemmal versus mitochondrial ATP-sensitive K+ channels
- Author
-
Driamov, Sergey, Bellahcene, Mohamed, Ziegler, André, Barbosa, Vânia, Traub, David, Butz, Silvia, Buser, Peter, Zaugg, Christian, Driamov, Sergey, Bellahcene, Mohamed, Ziegler, André, Barbosa, Vânia, Traub, David, Butz, Silvia, Buser, Peter, and Zaugg, Christian
- Abstract
: Short episodes of ischemia (ischemic preconditioning) protect the heart against ventricular arrhythmias during zero-flow ischemia and reperfusion. However, in clinics, many episodes of ischemia present a residual flow (low-flow ischemia). Here we examined whether ischemic preconditioning protects against ventricular arrhythmias during and after a low-flow ischemia and, if so, by what mechanism(s). Isolated rat hearts were subjected to 60 min of low-flow ischemia (12% residual coronary flow) followed by 60 min of reperfusion. Ischemic preconditioning was induced by two cycles of 5 min of zero-flow ischemia followed by 5 and 15 min of reperfusion, respectively. Arrhythmias were evaluated as numbers of ventricular premature beats (VPBs) as well as incidences of ventricular tachycardia (VT) and ventricular .brillation (VF) during low-flow ischemia and reperfusion. Ischemic preconditioning significantly reduced the number of VPBs and the incidence of VT and of VF during low-flow ischemia. This antiarrhythmic effect of preconditioning was abolished by HOE 140 (100 nM), a bradykinin B2 receptor blocker. Similar to preconditioning, exogenous bradykinin (10 nM) reduced the number of VPBs and the incidence of VT and of VF during low-flow ischemia. Furthermore, the antiarrhythmic effects of both ischemic preconditioning and bradykinin were abolished by glibenclamide (1 µM), a non-specific blocker of ATP-sensitive K+ (KATP) channels. Finally, the antiarrhythmic effects of both ischemic preconditioning and bradykinin were abolished by HMR 1098 (10 µM), a sarcolemmal KATP channel blocker but not by 5-hydroxydecanoate (100 µM), a mitochondrial KATP channel blocker. In conclusion, ischemic preconditioning protects against ventricular arrhythmias induced by low-flow ischemia, and this protection involves activation of bradykinin B2 receptors and subsequent opening of sarcolemmal but not of mitochondrial KATP channels
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.